GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer
GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal worth up to £268 million.
GlaxoSmithKline (GSK) has struck a deal to acquire exclusive rights to develop and commercialise an antibody-drug conjugate (ADC) from Syndivia targeting metastatic castration-resistant prostate cancer.
- The agreement is reported to be worth up to £268 million.
- The therapy addresses a significant unmet need given the limited targeted treatment options for this advanced form of prostate cancer.
GSK’s push to broaden its oncology pipeline.
Syndivia, a France-based biotech firm specialising in next-generation ADCs, has shown this candidate delivered enhanced tumour reduction in preclinical studies while maintaining an encouraging safety profile.
Author summary: GSK acquires ADC asset for prostate cancer.
More News
- ‘Every stitch has a story’ – Centenary of Remembrance in Portadown
- Elon Musk’s Unveils Grokipedia - IT News Africa | Business Technology, Telecoms and Startup News
- Africa: Saving the Pancake Tortoise - a 'Living Emblem' of Kenya's Natural Heritage
- In Review: Big-Ass Sword by Andreas Butzbach
- Kaishan signs steam supply agreement for 165-MW geothermal green ammonia facility in Kenya
- Banging bumper fun from 2000AD!
- Free trains to London for Armed Forces ahead of Remembrance events
- Çelikler to drill 11 geothermal exploration wells in two sites in Aydin, Türkiye
- 6 Restaurant Chains With the Best Silver Dollar Pancakes
- Konin, Poland officially starts operations of geothermal heating plant